Related Experiment Video
Updated: May 30, 2026

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography
Published on: August 11, 2023
[Development of morbidity and mortality in ANCA-associated vasculitis]
1Klinik für Rheumatologie und klinische Immunologie Klinikum Bad Bramstedt und Poliklinik für Rheumatologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland. reinhold-keller@rheuma-spezialisten.de
Abstract:
The outcome of ANCA (antineutrophil cytoplasmic antibody)-associated vasculitis (AAV) has been significantly improved due to the combined use of cyclophosphamide (CYC) and glucocorticosteroids. Recent studies demonstrated a normalization of life expectancy for several subgroups of AAV patients. Mortality is highest in the first year after diagnosis and infections are the most frequent cause of death. Older age and renal failure are associated with worse outcome. The use of Pneumocystis jiroveci prophylaxis and subsequent activity-adapted GC dose reduction (target: below 10 mg per day) can substantially reduce the risk of severe infections. Late sequelae of CYC medication, such as cystitis and malignancy should be recognized and can be minimized by the usage of uroprotection with mesna and avoidance of high cumulative CYC doses.
Related Concept Videos
Endocarditis II: Clinical Features of Infective Endocarditis
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Aneurysm I: Introduction

